MSOs Can't Wait for a Ruling That May Not Come
— Fixing Risk Now Doesn't Require an Answer From Washington

Every cannabis MSO's leadership keeps asking advisors when this resolves. The honest answer is that three separate processes are in motion, and none of them has a confirmed date.

Three Processes, Zero Confirmed Dates

Three things are moving at once, and it's worth being precise about which is which. First, the DEA's hearing on rescheduling the broader cannabis market concluded July 15, with post-hearing briefs due August 17 and no announced timeline after that. Second, the April 2026 order that already moved state-licensed medical cannabis to Schedule III is being challenged at the D.C. Circuit, docket 26-1136, where the court is still deciding threshold standing and stay questions, with a ruling on those questions expected within weeks. Third, Treasury's 280E apportionment guidance, previewed in April, still hadn't been formally published as of early August, and has said nothing about whether relief reaches back before 2026. An MSO waiting for "the ruling" to plan around is waiting for the wrong number of things to happen, at once, on no confirmed schedule.

What a Stay Would Actually Do to an MSO's Balance Sheet

The D.C. Circuit outcome matters most to balance sheets built on the assumption that medical rescheduling is durable. If the court grants both standing and a stay, the practical effect is that medical cannabis's Schedule III status, and the 280E relief tied to it, could be paused while the litigation continues. For an MSO that has already adjusted its tax position, or a buyer underwriting a deal on the assumption that a target's medical revenue is now 280E-free, that's not a remote scenario. Practitioners following the briefing expect a threshold ruling within weeks of this writing.

The Retroactivity Bet Some MSOs Already Made, and What It's Costing Them

Some MSOs already bet real money that rescheduling would reach backward, and the industry's own accounting shows how unsettled that bet still is. Across public operators, disputed 280E liabilities have reached roughly $1.6 billion. Trulieve, the largest claimant, still declines to book any tax benefit for years before 2026 in its own filings. Curaleaf released $97 million of reserves and took the benefit, while cautioning there's no assurance retroactive relief will be permitted. TerrAscend received an $8.3 million refund in 2024 on the same theory, and the Department of Justice sued in May 2026 to claw it back. For advisors valuing an MSO or structuring a deal, a target's 280E position needs the same diligence as any other contested liability: is it booked, contested, or already the subject of a government collection action.

What This Means for How You Advise

• Price the D.C. Circuit outcome into any deal or valuation touching medical cannabis revenue. A stay pending review is a live possibility in the next few weeks, not a distant hypothetical.
• Treat an MSO's booked 280E refund position as a diligence item, not a settled asset. Ask whether it's recognized under ASC 740, contested, or already the subject of a clawback action like the one against TerrAscend.
• Fix the parts of the cost structure that don't depend on any of these outcomes. A properly structured captive builds retained equity from an MSO's own risk management regardless of how the hearing, the D.C. Circuit case, or the Treasury guidance resolves.

Contact 3F Captive Services for a no-cost policy analysis of how a captive fits into an MSO's risk financing and deal readiness.

This post is for informational purposes only and does not constitute insurance, legal, or tax advice. Rescheduling status, 280E treatment, and litigation outcomes vary by entity and jurisdiction. Consult qualified legal, tax, and insurance advisors regarding your specific situation.

Sources

1. U.S. Court of Appeals for the District of Columbia Circuit, MMJ BioPharma Cultivation, et al. v. U.S. Department of Justice, Docket No. 26-1136.

2. Harris Sliwoski LLP, “Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test,” Canna Law Blog, July 24, 2026.

3. Shay Aaron Gilmore, “Cannabis 280E Relief: Who Keeps the $1.6 Billion?”, June 29, 2026.

4. Trulieve Cannabis Corp. Form 10-Q (Q1 2026); Curaleaf Holdings, Inc. SEC filing (Q1 2026); TerrAscend Corp. disclosures and reporting on U.S. v. TerrAscend (May 18, 2026).

5. DEA Administrative Law Judge Derek Julius, hearing schedule order concluding proceedings July 15, 2026; post-hearing briefs due August 17, 2026.

‍